Soluble CTLA4 mutant molecules and uses thereof

Details Soluble CTLA4 mutant molecules and uses thereof Soluble CTLA4 mutant molecules and uses thereof

2006-09-12

2006-09-12

Spector, Lorraine (Department: 1647)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Fusion protein or fusion polypeptide

C530S387300, C530S350000, C435S069700, C424S134100

Reexamination Certificate

active

07105166

ABSTRACT:
The present invention provides soluble CTLA4 mutant molecules which bind CD80 and/or CD86 antigen.

REFERENCES:
patent: 5434131 (1995-07-01), Linsley et al.
patent: 5637481 (1997-06-01), Ledbetter et al.
patent: 5770197 (1998-06-01), Linsley et al.
patent: 5773253 (1998-06-01), Linsley et al.
patent: 5844095 (1998-12-01), Linsley et al.
patent: 5851795 (1998-12-01), Linsley et al.
patent: 5885579 (1999-03-01), Linsley et al.
patent: 5885796 (1999-03-01), Linsley et al.
patent: 5916560 (1999-06-01), Larsen et al.
patent: 5958403 (1999-09-01), Strom et al.
patent: 5968510 (1999-10-01), Linsley et al.
patent: 5977318 (1999-11-01), Linsley et al.
patent: 5993800 (1999-11-01), Linsley et al.
patent: 6090914 (2000-07-01), Linsley et al.
patent: 6132992 (2000-10-01), Ledbetter et al.
patent: 6444792 (2002-09-01), Gray et al.
patent: 0 613 944 (1994-09-01), None
patent: 0 682 039 (1995-11-01), None
patent: WO 93/19767 (1993-10-01), None
patent: WO 94/28912 (1994-12-01), None
patent: WO 94/29436 (1994-12-01), None
patent: WO 95/33823 (1995-12-01), None
patent: WO 96/14865 (1996-05-01), None
patent: WO 98/31820 (1998-07-01), None
patent: WO 98/33513 (1998-08-01), None
patent: WO 98/56417 (1998-12-01), None
patent: WO 00/23115 (2000-04-01), None
patent: WO 01/54732 (2001-08-01), None
patent: WO 01/90122 (2001-11-01), None
patent: WO 01/92337 (2001-12-01), None
patent: WO 02/02638 (2002-01-01), None
Peach et al., “Complementarity Determining Region 1 (CDR1)- and CDR3-analogous in CTLA-4 and CD28 Determine the Binding to B7-1,” (1994) J. Exp. Med. 180:2049-2058. (Exhibit 236).
Morton et al., “Differential Effects of CTLA-4 Substitutions on the Binding of Human CD80 (B7-1) and CD86 (B7-2),” (1996) J. Immol.Feb. 1; 156:1047-1054. (Exhibit 237).
Sun, Hong et al., “Prevention of Chronic Rejection in Mouse Aortic Allografts by Combined Treatment with CTLA4-Ig and Anti-CD40 Ligand Monoclonal Antibody,” Transplantation, 1997, 64:1838-56 (Exhibit 239).
Souza, “Synergistic inhibition of established collagen induced arthritis (CIA) through dual inhibition of ICAM-1 and CD40L pathways,”Arthritis and Rhuematism, 1999, p. S60; abstract 64 (Exhibit 240).
Blazar, Bruce R. et al., “Coblockade of the LFAI:ICAM and CD28/CTLA4:B7 Pathways Is A Highly Effective Means of Preventing Acute Lethal Graft-Versus-Host Disease Induced by Fully Major Histocompatibility Complex-Disparate Donor Grafts,”Blood, 1995, 85:2607-18 (Exhibit 241).
Alegre et al., “Immunomudulation of transplant rejection using monoclonal antibodies and soluble receptors,”Dig. Dis. Sci., 1995, 40:58-64 (Exhibit 244).
Murakami et al., “Identification and characterization of an alternative cytotoxic T lymphocyte-associated protein 4 binding molecule on B cells,”Proc. Nat. Acad. Sci. USA, 1996, 3:7838-7842 (Exhibit 245).
Peach et al., “Both extracellaular immunoglobulin-like domains of CD80 contain residues critical for binding T cell surface receptors CTLA-4 and CD28,”J. Biol. Chem., 1995, 270):21181-21187 (Exhibit 246).
Fargeas et al., “Identification of Residues in the V Domain of CD80 (B7-1) Implicated in Functional Interactions with CD28 and CTLA4,”J. Exp. Med., 1995, 182:667-675 (Exhibit 247).
Steurer et al., “Ex Vivo Coating of Islet Cell Allografts with Murin CTLA4/Fc Promotes Graft Tolerance,”J. Immunol., 1995, 155:1165-1174 (Exhibit 248).
Guo et al., “Mutational Analysis and an Alternatively Spliced Product of B7 Defines Its CD28/CTLA4-binding Site on Immunoglobulin C-like Domain,”J. Exp. Med., 1995, 181:1345-1355 (Exhibit 249).
Peach et al., “CTLA4Ig: A Novel Immunoglobulin Chimera with Immunosuppressive Properties,”Methods, 1995, 8:116-123 (Exhibit 250).
Rattis et al., “Expression and function of B7-1 (CD80) and B7-2 (CD86) on human epidermal Langerhans cells,”Eur. J. Immunol., 1996, 26:449-453 (Exhibit 251).
Najafian, et al., “CTLA4-Ig: a novel immunosuppressive agent,”Exp. Opin. Invest. Drugs, 2000, 9:2147-2157 (Exhibit 255).
Schwartz, R., “Costimulation of T Lymphocytes: The Role of CD28, CTLA-4, and B7/BB1 in Interleukin-2 Production and Immunotherapy,”Cell, 1992, 71:1085-1088. (Exhibit 257).
Fanslow, William C. et al., “Regulation of Alloreactivity In Vivo by IL-4 and the Soluble IL-4 Receptor”The Journal of Immunology, 1991, 147:535-40 (Exhibit 69).
Brummell, David A. et al., “Probing the Combining Site of an Anti-Carbohydrate Antibody by Saturation-Mutagenesis: Role of the Heavy-Chain CDR3 Residues”Biochemistry, 1993, 32:1180-1187. (Exhibit 260).
Weissenhorn, Winifred et al., “VH-Related Idiotopes Detected By Site-Directed Mutagenesis, A Study Induced by the Failure to find CD4 Anti-Idiotypic antibodies Mimicking the cellular receptor of HIV1,”Journal of Immunology, 1992, 149: 1237-1241 (Exhibit 261).
Aruffo, Alenjandro and Brian Seed, “Molecular Cloning of a CD28 cDNA by a High-Efficiency COS Cell Expression System,” PNAS, Dec. 1987, 84:8573-7. (Exhibit 262).

Affiliated with

Also associated with

Rating

Soluble CTLA4 mutant molecules and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Soluble CTLA4 mutant molecules and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Soluble CTLA4 mutant molecules and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3562610